Tag: The Netherlands

MAPPING THE CLINICAL COPD QUESTIONNAIRE ONTO EQ-5D VALUES

Rotterdam, The Netherlands – The Clinical COPD Questionnaire (CCQ) is a widely-used questionnaire to assess the effectiveness of chronic obstructive pulmonary disease (COPD) treatments. However, it is not a preference-based measure, and hence cannot be directly used to estimate the

Posted in Announcements, Methodological Articles, Value in Health Tagged with: , , , , , , ,

IDENTIFYING THE FACTORS THAT ENHANCE POSITIVE DRUG REIMBURSEMENT RECOMMENDATION IN SCOTLAND

Rotterdam, The Netherlands – Given limited health care resources and rising expenditures on pharmaceuticals, policy makers are increasingly confronted with the challenging task to improve patient outcomes and reimburse new pharmaceutical interventions. Arguably, Scotland is often one of the first

Posted in Announcements, Health Policy Analyses, Value in Health Tagged with: , , , , , ,

CURRENT PRACTICE OF RCT-BASED MODELLING CAN LEAD TO WRONG RESEARCH PRIORITIES

Rotterdam, The Netherlands – The current practice of prioritizing research in the context of conditional reimbursement can lead to wrong decisions since it relies on randomized controlled trials (RCT) based cost-effectiveness models, which do not reflect all uncertainties that are

Posted in Methodological Articles, Value in Health Tagged with: , , , , ,

ISPOR ADDRESSES NEW CHALLENGES FOR IMPROVING EUROPEAN HEALTH CARE AT ANNUAL EUROPEAN CONGRESS

Princeton, NJ, USA, October 7, 2014 – The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold its 17th Annual European Congress in Amsterdam from November 8-12, 2014. The theme of this year’s congress is: “New Challenges for Improving

Posted in Announcements, ISPOR News & Press Tagged with: , ,

Does Outcomes Research Reduce Policy Maker Uncertainty?

Rotterdam, The Netherlands – Health care payers increasingly request additional data from clinical practice to assess whether a drug is worth public spending. The data gathered should reduce the initial uncertainty regarding the clinical and economic performance of expensive drugs in a

Posted in Comparative Effectiveness Research / Health Technology Assessment, Value in Health Tagged with: , , , ,

The QALY Model Upside-Down

Leiden, The Netherlands – The quality-adjusted life years (QALY) model is defined, in its most basic form, as life duration multiplied by an index in the 0-1 range representing the patients’ quality-of-life. The hazard function is a key concept in the statistical

Posted in Methodological Articles, Value in Health Tagged with: , , , ,

Pharmacoeconomic Guidelines Unclear On Dealing With Patient Differences

Maastricht, The Netherlands – Acknowledging patient heterogeneity in economic evaluations and subsequent reimbursement decisions may lead to more effective and/or efficient health care. Despite this potential gain, patient heterogeneity is still frequently neglected in economic evaluations.

Posted in Systematic Reviews, Value in Health Tagged with: , , , ,